Reason for request
Re-assessment of the actual benefit at the request of the Transparency
Clinical Benefit
Low |
Le service médical rendu par MEGACE 160 mg est faible dans le traitement palliatif des carcinomes du sein.
|
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
RgUH8rAhsfaFQ8pF